Literature DB >> 9637778

PKN interacts with a paraneoplastic cerebellar degeneration-associated antigen, which is a potential transcription factor.

H Takanaga1, H Mukai, H Shibata, M Toshimori, Y Ono.   

Abstract

PKN is a fatty acid-activated serine/threonine protein kinase, having a catalytic domain homologous to protein kinase C family. PKN has been recently reported to interact with a small GTP-binding protein Rho and cytoskeletal proteins such as neurofilament and alpha-actinin. To identify the new components of the PKN-signaling pathway, the yeast two-hybrid system was employed. Using the amino-terminal regulatory domain of PKN as a bait, cDNA encoding a neural antigen PCD17, which is recognized by characteristic antibodies of patients with paraneoplastic cerebellar degeneration, was isolated from a human brain cDNA library. The interaction between PKN and PCD17 was also determined by the in vitro binding analysis. PCD17 was coimmunoprecipitated with PKN from the lysate of COS7 cells transfected with both expression constructs for PKN and the amino-terminal region of PCD17. PCD17 was phosphorylated by PKN, and the extent of this phosphorylation was enhanced by addition of 40 microM arachidonic acid. The amino-terminal region of PCD17 could form a homodimer in vitro, and PCD17 fused to the Gal4 DNA binding domain showed the transcriptional transactivation of the chloramphenicol acetyltransferase reporter gene linked to 5 Gal4 binding sites and minimal promoter in rat C6 glioma cells. These results suggest the participation of PCD17 in gene expression and lead to a clue for elucidating the PKN signaling pathway from the cytosol to the nucleus. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637778     DOI: 10.1006/excr.1998.4060

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

Authors:  Varadha Balaji Venkadakrishnan; Adam D DePriest; Sangeeta Kumari; Dhirodatta Senapati; Salma Ben-Salem; Yixue Su; Giridhar Mudduluru; Qiang Hu; Eduardo Cortes; Elena Pop; James L Mohler; Gissou Azabdaftari; Kristopher Attwood; Rajal B Shah; Christina Jamieson; Scott M Dehm; Cristina Magi-Galluzzi; Eric Klein; Nima Sharifi; Song Liu; Hannelore V Heemers
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

2.  MicroRNA 452 regulates ASB8, NOL8, and CDR2 expression in colorectal cancer cells.

Authors:  Ji-Su Mo; Soo-Cheon Chae
Journal:  Genes Genomics       Date:  2021-01-04       Impact factor: 1.839

3.  The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.

Authors:  H J Okano; W Y Park; J P Corradi; R B Darnell
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

4.  A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.

Authors:  Eric Metzger; Judith M Müller; Stefano Ferrari; Reinhard Buettner; Roland Schüle
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

5.  A rho-binding protein kinase C-like activity is required for the function of protein kinase N in Drosophila development.

Authors:  Martha Betson; Jeffrey Settleman
Journal:  Genetics       Date:  2007-05-16       Impact factor: 4.562

6.  CDR2 antigen and Yo antibodies.

Authors:  Cecilie Totland; Nina K Aarskog; Tilo W Eichler; Mette Haugen; Jane K Nøstbakken; Sissel E Monstad; Helga B Salvesen; Sverre Mørk; Bjørn I Haukanes; Christian A Vedeler
Journal:  Cancer Immunol Immunother       Date:  2010-11-16       Impact factor: 6.968

Review 7.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

8.  Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.

Authors:  Manja Schubert; Debabrata Panja; Mette Haugen; Clive R Bramham; Christian A Vedeler
Journal:  Acta Neuropathol       Date:  2014-10-24       Impact factor: 17.088

Review 9.  Cell-mediated immune responses in paraneoplastic neurological syndromes.

Authors:  Mikolaj Piotr Zaborowski; Slawomir Michalak
Journal:  Clin Dev Immunol       Date:  2013-12-30

10.  Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegeneration.

Authors:  J-Y Hwang; J Lee; C-K Oh; H W Kang; I-Y Hwang; J W Um; H C Park; S Kim; J-H Shin; W-Y Park; R B Darnell; H-D Um; K C Chung; K Kim; Y J Oh
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.